His factory for life science startups has launched more than 100 companies, including Moderna.See where Noubar Afeyan lands on the #Forbes250: America's Greatest Innovators list: https://t.co/CFs11UNXUH (Photo: Michael Prince for Forbes) https://t.co/Uw0xnWBwqB ...

Core Insights - Nipah virus (NiV) poses a significant public health threat due to its pandemic potential and the absence of approved vaccines or treatments [2] - The virus has a high mortality rate ranging from 40% to 75% in reported outbreaks, with evidence of human-to-human transmission [2] - The World Health Organization has prioritized the development of safe and effective vaccines against Nipah virus [2] Group 1: Nipah Virus Overview - Nipah virus was first identified in Malaysia in 1998, causing viral encephalitis among pig farmers [2] - Since then, sporadic outbreaks have occurred in Singapore, India, and the Philippines, with Bangladesh experiencing annual outbreaks since 2001 [2] - The natural reservoir for the virus is fruit bats, which have a wide distribution, increasing the risk of future outbreaks [2] Group 2: Vaccine Development - A phase 1 clinical trial for an mRNA vaccine (mRNA-1215) developed by Moderna was published, showing promising safety and immunogenicity results [3][4] - The trial involved 40 healthy adults receiving varying doses of the vaccine, with the primary endpoints focusing on safety and tolerability [6] - Common adverse events included mild injection site pain (82%) and mild discomfort (40%), with no serious adverse events reported [7] Group 3: Immunogenicity Results - The vaccine induced strong antibody responses against the Pre-F and glycoprotein G, with neutralizing antibody titers observed within two weeks of initial vaccination [7] - Booster doses enhanced the immune response, maintaining high antibody levels for at least one year post-vaccination [7] - These findings support the continued clinical development of mRNA-1215 as a candidate vaccine for high-risk populations during Nipah virus outbreaks [13]

分组1 - Moderna, Inc. (MRNA) has experienced a decline in revenue since the end of the COVID-19 pandemic, indicating a lack of growth drivers for the company [1] - The company has been described as being in the doldrums, reflecting its struggles in the post-pandemic market environment [1] 分组2 - The analyst expresses a focus on undervalued and disliked companies with strong fundamentals and good cash flows, particularly in sectors like Oil & Gas and consumer goods [1] - Energy Transfer is highlighted as a company that was previously overlooked but has shown potential for substantial returns [1] - The analyst emphasizes a long-term value investing approach while also engaging in deal arbitrage opportunities [1]

Core Insights - Moderna characterized 2025 as a year of execution, achieving a revenue of $1.9 billion, which was at the high end of their projected range [2] - The approval of mNEXSPIKE, their second COVID vaccine, in June contributed significantly to their market presence for the fall season [2] - The company successfully reduced costs by over $2 billion in 2025, exceeding their initial target of $1 billion [3] - As a result of these efforts, Moderna ended the year with a cash balance of $8.1 billion, which includes $600 million from other sources [3]

Summary of Moderna FY Conference Call (March 10, 2026) Company Overview - **Company**: Moderna (NasdaqGS:MRNA) - **Fiscal Year**: 2025 - **Key Highlights**: Strong execution across revenue and cost management, significant progress in product pipeline Financial Performance - **Revenue**: $1.9 billion for FY 2025, at the high end of guidance range [2] - **Cost Reduction**: Achieved over $2 billion in cost savings, exceeding the $1 billion target set for 2025 [3] - **Cash Balance**: Ended 2025 with a cash balance of $8.1 billion, including $600 million from a credit facility [3] Product Pipeline Developments - **COVID-19 Vaccines**: - Spikevax approved for pediatric use (ages 6 months to 5 years) [4] - Positive data from Phase 3 flu vaccine study, application filed in the U.S. and other territories [4] - **Cancer Pipeline**: - Intismeran in Phase 3 for adjuvant melanoma, fully enrolled renal cell carcinoma study [4] - **Rare Diseases**: Fully enrolled study in PA, expecting readout in 2026 [42] Revenue Growth Projections - **2026 Guidance**: Up to 10% revenue growth expected, driven by: - Continued penetration of Spikevax in the U.S. (24% market share) [5] - Strategic partnerships with the U.K., Canada, and Australia, expected to generate $1 billion in international revenue [11] - **U.S. Sales Decline**: Anticipated decline in U.S. sales from $1.2 billion to $1 billion (20% decline) [11] Combination Vaccine Opportunities - **Flu-COVID Combination**: - Positive CHMP opinion received, expected approval in Europe later in 2026, contributing to revenue in 2027 [12] - Anticipated strong demand from single-payer systems internationally due to cost-effectiveness [15] - **U.S. Market**: Ongoing discussions with the FDA regarding the combination vaccine filing [13] Oncology Market Potential - **Adjuvant Melanoma**: - Multibillion-dollar market opportunity, with a 50/50 partnership with Merck [22] - Positive Phase 2 data with a hazard ratio of 0.51, aiming for similar or better results in Phase 3 [20] - **Future Indications**: Potential synergism with Keytruda, ongoing studies in various cancer types [24] Operating Expenses and Break-even Analysis - **R&D Spending**: Anticipated decrease in cash costs to $3.5 billion-$3.7 billion by 2027, with a need for revenue in that range to break even [36] - **Growth Drivers**: Expected contributions from European market openings and new partnerships in Latin America and Asia-Pacific [37] Rare Disease Program - **Partnership with Recordati**: Expected milestone payments of $160 million and tiered royalties based on sales for the PA program [42] Conclusion - **Outlook**: Exciting year ahead with multiple product approvals and significant growth opportunities in both existing and new markets [43]

Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent volatility and risks associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the financial models presented are based on the author's assumptions and are sensitive to input changes, which can significantly alter outputs [2]. - The predictions and opinions expressed reflect a probabilistic approach rather than absolute certainty [2]. Group 2 - The article states that past performance is not a guarantee of future results, and no specific investment recommendations are provided [3]. - It notes that the views expressed may not reflect those of Seeking Alpha as a whole, indicating a diversity of opinions among analysts [3]. - The article highlights that analysts may not be licensed or certified by any regulatory body, which could affect the reliability of the information presented [3].

Group 1 - Dr. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER), will leave his position in April, which has led to positive sentiment among investors regarding his controversial decisions during his tenure [1][2] - Moderna's shares are trending higher, with the potential for its mRNA-1010 vaccine to qualify for full approval in adults aged 65 and older, potentially avoiding the need for an additional costly efficacy study [3] - Stocks of several companies, including Solid Biosciences Inc. (up 12.15% to $7.57), Capricor Therapeutics Inc. (up 9.07%), Crispr Therapeutics AG (up 2.80% to $58.08), and Sarepta Therapeutics Inc. (up 4.31% to $17.43), have seen increases following the news of Dr. Prasad's departure [3] Group 2 - The resignation of Dr. Prasad could be beneficial for rare disease sponsors seeking to utilize single-arm studies and external controls for regulatory approval, as he was involved in denying an expedited review path for AMT-130 gene therapy [2] - Analysts from William Blair noted that investors are optimistic about the changes in leadership at CBER, which may lead to a more favorable regulatory environment for certain treatments [2]

Core Viewpoint - Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, is set to leave his position at the end of April after a controversial tenure marked by significant policy changes and staff complaints [1][2][3]. Group 1: Leadership and Tenure - Prasad's leadership at the FDA has been contentious, with reports of staff complaints regarding his management style [3]. - He initially intended to stay at the FDA for a full year but is departing after implementing several new policies [2]. Group 2: Regulatory Impact - Prasad's division is responsible for evaluating a wide range of treatments, including cancer drugs, gene therapies, and vaccines [3]. - His return to the FDA in August 2025 raised debates about the agency's regulatory direction, particularly due to his criticism of the biopharmaceutical industry and certain FDA approval pathways [4]. Group 3: Industry Reactions - The departure of Prasad follows a turbulent period that included high-profile controversies and stricter vaccine standards, stirring debate within the industry [4].

Core Viewpoint - Investors are increasingly concerned about the future of experimental drugs for hard-to-treat diseases due to recent rejections by the U.S. Food and Drug Administration (FDA) [1][4]. Group 1: FDA Rejections and Investor Sentiment - The FDA has denied or discouraged applications for at least eight drugs in the past year, including gene therapies for Huntington's disease and Hunter syndrome, as well as a drug for a blood condition [2]. - The FDA's rejections stem from issues with the evidence provided by companies, such as the lack of placebo-controlled studies and reliance on biomarkers instead of direct efficacy measurements [3]. - Companies have accused the FDA of reversing previous guidance, leading to investor wariness about the agency's unpredictability and its impact on future treatments [4]. Group 2: Regulatory Standards and Implications - Historically, the FDA was more lenient with drugs for rare diseases, allowing approvals based on less rigorous studies, which has drawn both support and criticism [5]. - The recent decisions have raised questions about whether the FDA's standards have changed for other drugs in development, as seen with UniQure being asked to conduct a new placebo-controlled study [6]. - Analysts are monitoring several companies, including Dyne Therapeutics and Taysha Gene Therapies, whose stock prices have declined this year amid regulatory uncertainty [8]. Group 3: Company Responses and Future Outlook - Dyne Therapeutics expressed confidence in its development strategy and ongoing dialogue with the FDA, while other companies like Taysha, Wave, and Lexeo declined to comment [9]. - Denali Therapeutics is awaiting a decision on its drug candidate for Hunter syndrome, with the FDA delaying its review by three months, now expected by April 5 [12]. - Some investors perceive a disconnect between the FDA's public commitments to flexibility and its recent decisions, leading to skepticism about the success of companies relying on flexible data acceptance [13]. Group 4: FDA's Position on Data Requirements - A senior FDA official stated that the agency's stance on using biomarkers for accelerated approval remains unchanged, and non-randomized data can still lead to full approval [15]. - The official emphasized that significant improvements in severely ill patients could warrant full regulatory approval even with limited data [16]. - The FDA requires randomized data primarily in cases where conditions are heterogeneous or when the potential for misleading results is high [17].

Core Insights - Three stocks, Trade Desk (TTD), Moderna (MRNA), and Strategy (MSTR), have recently bounced from lows, but analyst consensus shows differing levels of conviction regarding their recoveries [1] Group 1: Trade Desk (TTD) - Trade Desk rebounded 24.38% to $29.79 but remains 55.23% below its price from a year ago [1] - Of 38 analysts, 16 rate it Buy, 3 Strong Buy, 15 hold a neutral view, and 4 are negative, indicating a split sentiment [1] - Q4 2025 adjusted EPS was $0.59, beating estimates by 73.58%, while revenue of $846.79 million exceeded the consensus of $839.55 million [1] - Q1 2026 guidance suggests revenue of at least $678 million, implying roughly 10% growth, down from 18% in full-year 2025 [1] Group 2: Moderna (MRNA) - Moderna surged 82.54% year-to-date to $53.83, significantly above the consensus price target of $42.90, which is about 20% lower than current trading levels [1] - Among 24 analysts, 18 rate it Hold, 2 Sell, and 2 Strong Sell, indicating skepticism in the analyst community [1] - Q4 EPS was $2.11, below the estimate of $2.62, and revenue of $678 million beat the consensus by 10.73% [1] - Full-year revenue declined 40% from 2024, and the FDA's refusal-to-file letter on a flu vaccine removed a key catalyst [1] Group 3: Strategy (MSTR) - Strategy shares bounced to $139.81 but remain 54.69% below last year's price [1] - Analyst sentiment is the most bullish among the three, with 13 of 14 analysts rating it Buy or Strong Buy, and a consensus target of $394.38, implying 182% upside [1] - The company holds 713,502 BTC, and the Q4 net loss of $12.44 billion was primarily due to a $17.44 billion unrealized loss on digital assets [1] - Subscription services in the underlying software business grew 62.1% year-over-year [1]